Şirin, G. Et Al. 2017. Does 8-weeks Ledipasvir/Sofosbuvir Therapy Really Effective in Non-Cirrhotic, Treatment-naive Hepatitis C Genotype-1 Patients with HCV-RNA6 million IU/mL?. TASL-AASLD educational conference. , (İstanbul, Turkey).

Şirin, G., Duman, A. E., Yılmaz, H., İslamoğlu, Z., Çelebi, A., Şentürk, Ö., ... Hülagü, S.(2017). Does 8-weeks Ledipasvir/Sofosbuvir Therapy Really Effective in Non-Cirrhotic, Treatment-naive Hepatitis C Genotype-1 Patients with HCV-RNA6 million IU/mL? . TASL-AASLD educational conference., İstanbul, Turkey

Şirin, GÖKTUĞ Et Al. "Does 8-weeks Ledipasvir/Sofosbuvir Therapy Really Effective in Non-Cirrhotic, Treatment-naive Hepatitis C Genotype-1 Patients with HCV-RNA6 million IU/mL?," TASL-AASLD educational conference., İstanbul, Turkey, 2017

Şirin, GÖKTUĞ Et Al. "Does 8-weeks Ledipasvir/Sofosbuvir Therapy Really Effective in Non-Cirrhotic, Treatment-naive Hepatitis C Genotype-1 Patients with HCV-RNA6 million IU/mL?." TASL-AASLD educational conference. , İstanbul, Turkey, 2017

Şirin, G. Et Al. (2017) . "Does 8-weeks Ledipasvir/Sofosbuvir Therapy Really Effective in Non-Cirrhotic, Treatment-naive Hepatitis C Genotype-1 Patients with HCV-RNA6 million IU/mL?." TASL-AASLD educational conference. , İstanbul, Turkey.

@conferencepaper{conferencepaper, author={GÖKTUĞ ŞİRİN Et Al. }, title={Does 8-weeks Ledipasvir/Sofosbuvir Therapy Really Effective in Non-Cirrhotic, Treatment-naive Hepatitis C Genotype-1 Patients with HCV-RNA6 million IU/mL?}, congress name={TASL-AASLD educational conference.}, city={İstanbul}, country={Turkey}, year={2017}}